Chembio Diagnostics develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The Company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, a DPP HIV-Syphilis multiplex test, and a test for the detection of Hepatitis-C. Chembio Diagnostics sells its products under a number of brands and labels. The Company has collaboration agreements to develop POC diagnostic tests for traumatic brain injury, a specific type of cancer and an undisclosed biomarker.

Type
Public
HQ
Medford, US
Founded
1985
Size (employees)
131 (est)
Chembio was founded in 1985 and is headquartered in Medford, US
Report incorrect company information

Key People/Management at Chembio

John Sperzel

John Sperzel

President and Chief Executive Officer
Neil Goldman

Neil Goldman

Executive VP and Chief Financial Officer
Sharon Klugewicz

Sharon Klugewicz

President, Americas Region
Robert Passas

Robert Passas

President, EMEA and APAC Regions
Javan Esfandiari

Javan Esfandiari

Chief Science and Technology Officer
Tom Ippolito

Tom Ippolito

VP, Regulatory Affairs
Show more

Chembio Office Locations

Chembio has an office in Medford
Medford, US (HQ)
3661 Horseblock Road
Show all (1)
Report incorrect company information

Chembio Financials and Metrics

Chembio Financials

Chembio's revenue was reported to be $24.02 m in FY, 2017
USD

Revenue (FY, 2017)

24 m

Gross profit (FY, 2017)

11.1 m

Gross profit margin (FY, 2017), %

46.2%

Net income (FY, 2017)

(6.4 m)

EBIT (FY, 2017)

(6.5 m)

Market capitalization (16-Feb-2018)

5.1 m

Cash (31-Dec-2017)

3.8 m

EV

1.5 m
Chembio's current market capitalization is $5.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

29.5 m27.6 m24.3 m17.9 m24 m

Revenue growth, %

(6%)(12%)(26%)

Cost of goods sold

17.2 m16.8 m13.8 m9.4 m12.9 m

Gross profit

12.3 m10.8 m10.5 m8.5 m11.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

9.6 m5.8 m7.4 m7.3 m6.2 m6.7 m6.9 m6.6 m3.3 m3.7 m6.3 m4.1 m

Cost of goods sold

5.6 m3.5 m4.4 m4.7 m3.5 m3.7 m4 m3.4 m1.7 m1.8 m3.2 m2.2 m

Gross profit

4.1 m2.3 m3 m2.7 m2.7 m3 m2.9 m3.2 m1.6 m2 m3.1 m1.9 m

Gross profit Margin, %

42%39%40%36%43%45%42%48%48%52%49%46%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.7 m4.6 m5.4 m10.6 m3.8 m

Accounts Receivable

525.6 m

Inventories

3.2 m3.6 m3.6 m3.3 m4.4 m

Current Assets

18.5 m17.7 m12.6 m18.1 m10.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

8 m9.1 m6.8 m3.7 m2.8 m1.6 m1.1 m2.7 m1.4 m12.2 m5.6 m3.7 m

Inventories

3.7 m3.6 m4.1 m4 m3.7 m3.8 m3 m3.4 m3.5 m3.4 m3.8 m5 m

Current Assets

18 m17.2 m17.5 m17 m16.2 m15.7 m15.2 m12 m10.4 m20.6 m15.9 m14.1 m

PP&E

1.8 m1.9 m2.1 m2.1 m3 m2.8 m2.6 m2.2 m2 m1.8 m1.9 m2.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

530.8 k(1.1 m)(2.4 m)(13.3 m)(6.4 m)

Depreciation and Amortization

607.8 k739.3 k1.4 m1.1 m1.3 m

Inventories

(700.7 k)(449.6 k)60.3 k242.8 k(1.1 m)

Accounts Payable

182.5 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

716.7 k(224.7 k)(146 k)(270.6 k)(303.6 k)(8.3 m)(2.1 m)(1.6 m)

Inventories

4.1 m4 m3.7 m3.8 m3 m3.4 m3.5 m3.4 m3.8 m
USDY, 2017

EV/EBIT

-0.2 x

EV/CFO

-0.3 x

Revenue/Employee

183.3 k

Financial Leverage

1.3 x
Show all financial metrics

Chembio Operating Metrics

FY, 2016

Patents (US)

4

Products

3
Show all operating metrics
Report incorrect company information